Shuishu Wang

National Institutes of Health — United States

Immunology and Microbiology · Life Sciences

30h-index3.5kcitations102works3.52yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

HIV Research and Treatment(23), Monoclonal and Polyclonal Antibodies Research(20), SARS-CoV-2 and COVID-19 Research(15), RNA and protein synthesis mechanisms(9), vaccines and immunoinformatics approaches(9)

Publications102 total

Vaccine Elicitation of HIV-1 Neutralizing Antibodies Against Both V2 Apex and Fusion Peptide in Rhesus Macaques
2025Open Access
The N terminus of H3-influenza hemagglutinin as a site-of-vulnerability to neutralizing antibody
Structure·2025Open Access
Weak Supervision Techniques towards Enhanced ASR Models in Industry-level CRM Systems
arXiv (Cornell University)·2025Open Access
Weak Supervision Techniques Towards Enhanced ASR Models in Industry-Level CRM Systems
Communications in computer and information science·2025
Design, synthesis, and bio-evaluation of C1-aryl galantamine derivatives
Fitoterapia·2025· 1 cited
Pricing negative externalities in social networks
Journal of Mathematical Economics·2025
Towards robust and effective visual localization
2025
Design, Synthesis, and Bio-Evaluation of C2-Aryl Galantamine Derivatives
SSRN Electronic Journal·2025Open Access
The N Terminus of H3-Influenza Hemagglutinin as a Site-of-Vulnerability to Neutralizing Antibody
SSRN Electronic Journal·2025Open Access
Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide
Frontiers in Immunology·2024· 1 citedOpen Access
Potent and broad HIV-1 neutralization in fusion peptide-primed SHIV-infected macaques
Cell·2024· 22 citedOpen Access
Vaccine-elicited and naturally elicited antibodies differ in their recognition of the HIV-1 fusion peptide
2024Open Access
Anti-idiotype isolation of a broad and potent influenza A virus-neutralizing human antibody
Frontiers in Immunology·2024· 6 citedOpen Access
Cholesterol reduction by immunization with a PCSK9 mimic
Cell Reports·2024· 3 citedOpen Access
Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1
Advanced Science·2024· 5 citedOpen Access
Long trimer-immunization interval and appropriate adjuvant reduce immune responses to the soluble HIV-1-envelope trimer base
iScience·2024· 6 citedOpen Access
Cleavage-intermediate Lassa virus trimer elicits neutralizing responses, identifies neutralizing nanobodies, and reveals an apex-situated site-of-vulnerability
Nature Communications·2024· 15 citedOpen Access
Extraordinary Titer and Broad Anti-SARS-CoV-2 Neutralization Induced by Stabilized RBD Nanoparticles from Strain BA.5
Vaccines·2023· 9 citedOpen Access
Structural basis of glycan276-dependent recognition by HIV-1 broadly neutralizing antibodies
UNC Libraries·2023Open Access
Structure-based design of a single-chain triple-disulfide-stabilized fusion-glycoprotein trimer that elicits high-titer neutralizing responses against human metapneumovirus
PLoS Pathogens·2023· 12 citedOpen Access
page 1 of 6Next →

Frequent Co-authors

Peter D. Kwong(26), Tongqing Zhou(24), Baoshan Zhang(24), John R. Mascola(23), Yaroslav Tsybovsky(21), Li Ou(14), Adam S. Olia(13), Lawrence Shapiro(13), Reda Rawi(13), Gwo‐Yu Chuang(12), Jason Gorman(11), I‐Ting Teng(11), Alexandra F. Nazzari(10), Sijy O’Dell(10), Raffaello Verardi(10), Tyler Stephens(9), Kai Xu(9), Chen‐Hsiang Shen(9), Edward K. Sarfo(9), Mallika Sastry(8)